Intravenous immunoglobulin therapy for asthma: time for a closer look?
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The need for a pooled intravenous immunoglobulin preimprovement, sparing of oral glucocorticoids and absence of drug-induced morbidity". paration capable of passive transference of broad based humoral immunity was first recognised following the deLess favourable conclusions were reached by Jakobsson and colleagues. 4 They treated 14 adolescents requiring scription of congenital agammaglobulinaemia by Bruton. It was subsequently recognised that this treatment, originally inhaled glucocorticoids (400-2000 g daily) to keep them "almost free from symptoms" -that is, requiring no more intended to restore immune deficiency, actually appeared to have therapeutic effects in diseases involving immune than two dosages of inhaled 2 agonist daily. Owing to ethical constraints, the children were offered intravenous effector mechanisms, most notably "autoimmune" diseases such as immune thrombocytopenia.
1 Intravenous imimmunoglobulin therapy or entry to an untreated "reference" group in an open fashion. Nine patients who chose munoglobulin therapy is currently being evaluated for a possible therapeutic benefit in many other such diseases the treatment were commenced on intravenous immunoglobulin at an intended dosage of 1 g/kg on a single including rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, myasthenia gravis, and day monthly for five months. Treatment with the high dosages used by Mazer and Gelfand was considered "too others.
It is increasingly recognised that asthma is associated expensive". This dosage had to be decreased to 0.5 g/kg after the first infusion because it caused severe headache, with chronic, cell-mediated inflammation of the bronchial mucosa in which cytokine products of activated T cells, and then progressively increased (mean dosage 0.8 g/kg). Even at these lower dosages, infusions were frequently especially those which are implicated in selective eosinophil accumulation, play a prominent role. Evidence suggests accompanied by fever and rigors. During the infusion period six patients were able to reduce dosages of inhaled that glucocorticoids ameliorate asthma at least partly through inhibition of activated T cells and elaboration of glucocorticoid (from a mean of 720 g/day to 400 g/day) whereas three were not. Histamine bronchial reactivity was their cytokine products.
2 For this reason there has been interest in the investigation of other "anti-inflammatory" or also reduced (mean PC 20 0.33-1.23 mg/ml), as were total symptom scores. These differences, by comparison with the "immunosuppressive" agents for their possible therapeutic benefits in asthma. Since many of these agents have po-"reference" group, were not maintained after 10 additional months of follow up. Mean serum IgG concentrations tentially serious unwanted effects, attention has generally been focused on those asthmatic patients who continue to before (11.6 g/l) and four months after (11.4 g/l) the infusions were almost identical, as were serum total IgE have severe disease despite properly administered, maximal topical glucocorticoid therapy and additional continuous concentrations. In addition, serum concentrations of IgG anti-IgE antibodies and eosinophil cationic protein were systemic therapy. With such patients it is perceived that the benefits of amelioration of the disease and reduction unchanged. These authors concluded that the effects of intravenous immunoglobulin therapy were "small and temor abolition of systemic glucocorticoid therapy, with its well recognised hazards, might outweigh the risks.
porary, and the treatment complicated and expensive". They also hypothesised that some of the improvement The possible efficacy of intravenous immunoglobulin therapy for asthma has been investigated in two open observed in the study of Mazer and Gelfand might have reflected the effects of immunoglobulin replacement, since uncontrolled studies on children. Mazer and Gelfand 3 treated eight children who required continuous systemic they considered the mean serum IgG concentration before treatment in these children (5.85 g/l) to be abnormally low, glucocorticoid therapy for asthma control with intravenous immunoglobulin in a dose of 1 g/kg as a 6% solution on and a beneficial effect of intravenous immunoglobulin therapy had previously been demonstrated in asthmatic two consecutive days monthly for a total of six months (seven infusions). This regime was based on those used children with hypogammaglobulinaemia.
5
A further open study of the effects of intravenous imfor the treatment of autoimmune diseases with intravenous immunoglobulin. Intravenous immunoglobulin therapy almunoglobulin therapy in two severe glucocorticoiddependent adult asthmatic patients is reported in this issue lowed alternate-day prednisone dosages, which were claimed to be the lowest possible for stable maintenance, of Thorax. 6 These patients were labelled "glucocorticoid insensitive" since they had severe airways obstruction (with to be reduced from 32.5 mg to 11.5 mg. The mean forced expiratory volume in one second (FEV 1 ) -which was near high spontaneous variability) despite high dosages of systemic glucocorticoids with a poor clinical response to normal anyway before treatment in most of the childrenand the concentration of methacholine provoking a fall in further escalation of therapy. In addition, peripheral blood T cells from these patients were said to show "decreased FEV 1 of 20% (PC 20 ) did not change significantly, although diary symptom scores and 2 agonist usage were sigsensitivity" to dexamethasone in vitro. 7 Treatment of both patients with intravenous immunoglobulin (2 g/kg on a nificantly reduced. The mean serum total IgE concentrations were slightly but significantly reduced, while single day monthly on four or six occasions) allowed a marked reduction in the dose of oral glucocorticoids mean serum IgG concentrations were increased from 5.85 g/l before treatment to 12.4 g/l four months after accompanied by improvements in FEV 1 and variability of PEF. In one of these patients bronchial biopsy specimens completion of the infusions. Unwanted effects of treatment were apparently too trivial to warrant specific docutaken before and after four doses of intravenous immunoglobulin showed reductions in the numbers of T cells mentation. The authors concluded that intravenous immunoglobulin therapy was associated with "clinical and cells expressing the T cell activation marker CD25 in group.bmj.com on June 21, 2017 -Published by http://thorax.bmj.com/ Downloaded from the bronchial mucosa, while flow cytometric analysis of It is self-evident that uncontrolled, open label studies such as those discussed here are impossible to interpret peripheral blood T cells showed reductions in the percentages of both CD4 and CD8 cells expressing the acsince they do not allow for the power of the placebo effect and take no account of spontaneous variability in asthma tivation markers CD25 and HLA-DR. The serum concentration of total IgE was reduced, while that of total severity. Furthermore, little is known about possible spontaneous temporal variability of inflammatory cell numbers IgG was increased. In addition, these authors showed increased binding of the cytokine IL-8 to IgG autoand their activation states in the peripheral blood and bronchial mucosa of asthmatic subjects. Nevertheless, antibodies in the serum of this patient following treatment. The serum concentration of eosinophil cationic protein these studies arguably justify the need for larger placebo controlled trials of the possible benefits of intravenous was also reduced. Again, unwanted effects of therapy were presumably sufficiently mild as not to merit specific immunoglobulin therapy in glucocorticoid dependent asthma. It is to be hoped that the cost of such trials does documentation.
How might intravenous immunoglobulin exert an antinot prove prohibitive. asthma effect? Mazer and Gelfand 3 postulated that intra- 
